Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to a consortium led by Hong Kong-based private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals that include China. Financial terms were not disclosed.
The Japanese cosmetics group frames the divestment as part of its 2030 Medium-Term Strategy, which seeks to improve profitability and capital efficiency. Shiseido said it intends to direct management resources toward businesses where it has the strongest competitive advantage and to concentrate on priority brands and higher-growth opportunities. It described China as strategically important and attractive, while noting that e-commerce expansion, changing consumer behavior and a more diverse set of market participants are reshaping competition there.
Transaction structure and handover
Under the agreement, funds managed by IDG Capital will hold 95% of SLC's equity through two special purpose vehicles. A limited partnership enterprise established mainly by SLC's new management team will hold the remaining 5%. The transaction includes SLC's Beijing factory and production equipment.
Shiseido expects independent operation under IDG to support SLC's sustainable growth and brand value. To assist the handover, Shiseido will license the intellectual property rights that IDG needs to run the business. For a specified period after the transfer, it will also provide support for new product development, technical assistance for stable supply of existing products, and continued supply of raw materials and selected products. Shiseido said this transitional collaboration is intended to maintain SLC's innovation capabilities, product quality and business continuity.
Joint venture background
SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. The company has sold the C-beauty brand Aupres since 1994. With the current joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan's 35% stake, giving it full ownership before the sale.
Shiseido said the China subsidiary requires continued investment in product innovation and digital capabilities. The divestment, according to the company, allows the group to focus on priority brands and higher-growth opportunities.
Profit recovery context
The sale was announced days after Shiseido reported a 124.3% increase in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales rose 0.7%. Shiseido also raised its full-year core operating profit forecast to ¥87 billion (US$546 million) from ¥59 billion (US$433 million).
